153 related articles for article (PubMed ID: 38023174)
1. Subpopulation treatment effect pattern plot analysis: a prognostic model for distant recurrence-free survival to estimate delayed adjuvant chemotherapy initiation effect in triple-negative breast cancer.
Morante Z; Ferreyra Y; Pinto JA; Valdivieso N; Castañeda C; Vidaurre T; Valencia G; Rioja P; Fuentes H; Cotrina JM; Neciosup S; Gomez HL
Front Oncol; 2023; 13():1193927. PubMed ID: 38023174
[TBL] [Abstract][Full Text] [Related]
2. Impact of the Delayed Initiation of Adjuvant Chemotherapy in the Outcome of Triple Negative Breast Cancer.
Morante Z; Ruiz R; Araujo JM; Pinto JA; Cruz-Ku G; Urrunaga-Pastor D; Namuche F; Flores C; Mantilla R; Luján MG; Fuentes H; Schwarz L; Aguilar A; Neciosup S; Gómez HL
Clin Breast Cancer; 2021 Jun; 21(3):239-246.e4. PubMed ID: 33221201
[TBL] [Abstract][Full Text] [Related]
3. Clinical impact of delaying initiation of adjuvant chemotherapy in patients with breast cancer.
Gagliato Dde M; Gonzalez-Angulo AM; Lei X; Theriault RL; Giordano SH; Valero V; Hortobagyi GN; Chavez-Macgregor M
J Clin Oncol; 2014 Mar; 32(8):735-44. PubMed ID: 24470007
[TBL] [Abstract][Full Text] [Related]
4. Survival according to the site of metastasis in triple-negative breast cancer patients: The Peruvian experience.
Piedra-Delgado L; Chambergo-Michilot D; Morante Z; Fairen C; Jerves-Coello F; Luque-Benavides R; Casas F; Bustamante E; Razuri-Bustamante C; Torres-Roman JS; Fuentes H; Gomez H; Narvaez-Rojas A; De la Cruz-Ku G; Araujo J
PLoS One; 2024; 19(2):e0293833. PubMed ID: 38300959
[TBL] [Abstract][Full Text] [Related]
5. Association between initiation of adjuvant chemotherapy beyond 30 days after surgery and overall survival among patients with triple-negative breast cancer.
Heeg E; Marang-van de Mheen PJ; Van Maaren MC; Schreuder K; Tollenaar RAEM; Siesling S; Bos MEMM; Vrancken Peeters MTFD
Int J Cancer; 2020 Jul; 147(1):152-159. PubMed ID: 31721193
[TBL] [Abstract][Full Text] [Related]
6. Does time to adjuvant chemotherapy (TTC) affect outcomes in patients with triple-negative breast cancer?
Pomponio MK; Keele LJ; Fox KR; Clark AS; Matro JM; Shulman LN; Tchou JC
Breast Cancer Res Treat; 2019 Aug; 177(1):137-143. PubMed ID: 31119565
[TBL] [Abstract][Full Text] [Related]
7. Delayed Initiation of Adjuvant Chemotherapy Among Patients With Breast Cancer.
Chavez-MacGregor M; Clarke CA; Lichtensztajn DY; Giordano SH
JAMA Oncol; 2016 Mar; 2(3):322-9. PubMed ID: 26659132
[TBL] [Abstract][Full Text] [Related]
8. A seven-gene signature can predict distant recurrence in patients with triple-negative breast cancers who receive adjuvant chemotherapy following surgery.
Park YH; Jung HH; Do IG; Cho EY; Sohn I; Jung SH; Kil WH; Kim SW; Lee JE; Nam SJ; Ahn JS; Im YH
Int J Cancer; 2015 Apr; 136(8):1976-84. PubMed ID: 25537444
[TBL] [Abstract][Full Text] [Related]
9. A prognostic signature based on three-genes expression in triple-negative breast tumours with residual disease.
Pinto JA; Araujo J; Cardenas NK; Morante Z; Doimi F; Vidaurre T; Balko JM; Gomez HL
NPJ Genom Med; 2016; 1():15015. PubMed ID: 29263808
[TBL] [Abstract][Full Text] [Related]
10. Prognostic analysis of triple-negative breast cancer patients treated with adjuvant chemotherapy of fluorouracil, epirubicin and cyclophosphamide.
Sun W; Li C; Liu M; Liu W; Yang C; Cai LI
Oncol Lett; 2016 Mar; 11(3):2320-2326. PubMed ID: 26998170
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Factors and Models for Elderly (≥70 Years Old) Primary Operable Triple-Negative Breast Cancer: Analysis From the National Cancer Database.
Tang Z; Ji Y; Min Y; Zhang X; Xu W; Zhao L; Zhang J; Long L; Feng J; Wen Y
Front Endocrinol (Lausanne); 2022; 13():856268. PubMed ID: 35370936
[TBL] [Abstract][Full Text] [Related]
12. Survival outcome assessment for triple-negative breast cancer: a nomogram analysis based on integrated clinicopathological, sonographic, and mammographic characteristics.
Sheng DL; Shen XG; Shi ZT; Chang C; Li JW
Eur Radiol; 2022 Oct; 32(10):6575-6587. PubMed ID: 35759017
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of ERBB4 expression in patients with triple negative breast cancer.
Kim JY; Jung HH; Do IG; Bae S; Lee SK; Kim SW; Lee JE; Nam SJ; Ahn JS; Park YH; Im YH
BMC Cancer; 2016 Feb; 16():138. PubMed ID: 26907936
[TBL] [Abstract][Full Text] [Related]
14. Long-term survival outcomes of triple-receptor negative breast cancer survivors who are disease free at 5 years and relationship with low hormone receptor positivity.
Reddy SM; Barcenas CH; Sinha AK; Hsu L; Moulder SL; Tripathy D; Hortobagyi GN; Valero V
Br J Cancer; 2018 Jan; 118(1):17-23. PubMed ID: 29235566
[TBL] [Abstract][Full Text] [Related]
15. Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial.
Gelber RD; Wang XV; Cole BF; Cameron D; Cardoso F; Tjan-Heijnen V; Krop I; Loi S; Salgado R; Kiermaier A; Frank E; Fumagalli D; Caballero C; de Azambuja E; Procter M; Clark E; Restuccia E; Heeson S; Bines J; Loibl S; Piccart-Gebhart M;
Eur J Cancer; 2022 May; 166():219-228. PubMed ID: 35313167
[TBL] [Abstract][Full Text] [Related]
16. Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy.
Bonsang-Kitzis H; Chaltier L; Belin L; Savignoni A; Rouzier R; Sablin MP; Lerebours F; Bidard FC; Cottu P; Sastre-Garau X; Laé M; Pierga JY; Reyal F
PLoS One; 2015; 10(12):e0144359. PubMed ID: 26684197
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant chemotherapy in pT1ab node-negative triple-negative breast carcinomas: Results of a national multi-institutional retrospective study.
de Nonneville A; Gonçalves A; Zemmour C; Cohen M; Classe JM; Reyal F; Colombo PE; Jouve E; Giard S; Barranger E; Sabatier R; Bertucci F; Boher JM; Houvenaeghel G
Eur J Cancer; 2017 Oct; 84():34-43. PubMed ID: 28780480
[TBL] [Abstract][Full Text] [Related]
18. Treatment With Adjuvant Abemaciclib Plus Endocrine Therapy in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy: A Prespecified Analysis of the monarchE Randomized Clinical Trial.
Martin M; Hegg R; Kim SB; Schenker M; Grecea D; Garcia-Saenz JA; Papazisis K; Ouyang Q; Lacko A; Oksuzoglu B; Reeves J; Okera M; Testa L; Shimizu C; Denduluri N; Adamchuk H; Dakhil S; Wei R; Forrester T; Fernandez MM; Zimmermann A; Headley D; Johnston SRD
JAMA Oncol; 2022 Aug; 8(8):1190-1194. PubMed ID: 35653145
[TBL] [Abstract][Full Text] [Related]
19. A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.
Prat A; Guarneri V; Paré L; Griguolo G; Pascual T; Dieci MV; Chic N; González-Farré B; Frassoldati A; Sanfeliu E; Cejalvo JM; Muñoz M; Bisagni G; Brasó-Maristany F; Urso L; Vidal M; Brandes AA; Adamo B; Musolino A; Miglietta F; Conte B; Oliveira M; Saura C; Pernas S; Alarcón J; Llombart-Cussac A; Cortés J; Manso L; López R; Ciruelos E; Schettini F; Villagrasa P; Carey LA; Perou CM; Piacentini F; D'Amico R; Tagliafico E; Parker JS; Conte P
Lancet Oncol; 2020 Nov; 21(11):1455-1464. PubMed ID: 33152285
[TBL] [Abstract][Full Text] [Related]
20. A Risk Stratification Model for Predicting Overall Survival and Surgical Benefit in Triple-Negative Breast Cancer Patients With
Wang Z; Wang H; Sun X; Fang Y; Lu SS; Ding SN; Chen XS; Shen KW
Front Oncol; 2020; 10():14. PubMed ID: 32038988
[No Abstract] [Full Text] [Related]
[Next] [New Search]
